Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

被引：0
|
作者：
Ji, Yanping [1 ]
Tang, Baolin [2 ]
Zhu, Xiaoyu [2 ]
Liu, Huilan [2 ]
Song, Kaidi [2 ]
Wan, Xiang [2 ]
Yao, Wen [2 ]
Sun, Guangyu [2 ]
Wang, Jian [3 ]
Sun, Zimin [2 ]
机构：
[1] Anhui Med Univ, Anhui Prov Hosp, Hefei, Peoples R China
[2] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei, Peoples R China
[3] Univ Sci & Technol China, Anhui Prov Hosp, Hefei, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130138
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5677
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease
    Modi, Badri
    Hernandez-Henderson, Michael
    Kopp, Erin
    Yang, Dongyun
    Huelsman, Karen
    Sollena, Pietro
    Zain, Jasmine M.
    Ali, Haris
    Al Malki, Monzr M.
    Spielberger, Ricardo
    Dadwal, Sanjeet
    Salhotra, Amandeep
    Forman, Stephen J.
    Parker, Pablo
    Nakamura, Ryotaro
    BLOOD, 2017, 130
  • [22] The Treatment of Chronic Graft-Versus-Host Disease
    Wolff, Daniel
    Bertz, Hartmut
    Greinix, Hildegard
    Lawitschka, Anita
    Halter, Joerg
    Holler, Ernst
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (43): : 732 - I
  • [23] Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
    Denk, Alexander
    Edinger, Matthias
    Weber, Daniela
    Holler, Ernst
    Fante, Matthias
    Meedt, Elisabeth
    Gunes, Sibel
    Poeck, Hendrik
    Mittermaier, Cornelia
    Herr, Wolfgang
    Wolff, Daniel
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3071 - 3081
  • [24] Ruxolitinib treatment for steroid-refractory graft-versus-host disease
    Park, Han-Seung
    Lee, Je-Hwan
    Lee, Jung-Hee
    Choi, Eun-Ji
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo-Hyung
    BONE MARROW TRANSPLANTATION, 2019, 54 : 323 - 324
  • [25] Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease
    Maas-Bauer, Kristina
    Kiote-Schmidt, Chrissoula
    Bertz, Hartmut
    Apostolova, Petya
    Waesch, Ralph
    Ihorst, Gabriele
    Finke, Juergen
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2021, 56 (04) : 909 - 916
  • [26] Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease
    Algeri, Mattia
    Becilli, Marco
    Locatelli, Franco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (11) : 1299 - 1313
  • [27] PUVA as adjuvant primary or salvage treatment for chronic graft-versus-host disease (GVHD)
    Thompson, D
    Sullivan, K
    Seidel, K
    Erickson, K
    Flowers, M
    Siadak, M
    Appelbaum, F
    Olerud, J
    Storb, R
    BLOOD, 1995, 86 (10) : 1581 - 1581
  • [28] PUVA AS ADJUVANT PRIMARY OR SALVAGE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)
    THOMPSON, D
    SULLIVAN, K
    SEIDEL, K
    ERICKSON, K
    FLOWERS, M
    SIADAK, M
    APPELBAUM, F
    OLERUD, J
    STORB, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (04) : 659 - 659
  • [29] Tongue graft-versus-host disease: remission with ruxolitinib
    Grafanaki, Katerina
    Lygeros, Spyridon
    Spyridonidis, Alexandros
    Liga, Maria
    BMJ CASE REPORTS, 2022, 15 (05)
  • [30] Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease
    Cook, Eleanor
    Dong, Min
    Chiang, Samuel C. C.
    Luedeke, David
    Lake, Kelly E.
    Hoerth, Colin
    Deavy, Marisa
    Setchell, Kenneth D. R.
    Zhao, Junfang
    Galletta, Thomas
    Punt, Nieko
    Teusink-Cross, Ashley
    Davies, Stella M.
    Marsh, Rebecca A.
    Mehta, Parinda
    Khandelwal, Pooja
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (05): : 528.e1 - 528.e12
12345